Thursday, September 6th 2018

Session 1  9:00-12:45

9:00 Official opening of the conference  
Dean Gosset

**HCHWA-D**

Moderators: Mark van Buchem (Leiden, NL) & Gaël Nicolas (Rouen, FR)

9:15 Introductory talk  
Jolanda Blom (HCHWA-D Patient Organization)

9:25 Imaging markers of presymptomatic HCHWA-D patients.  
Sanneke van Rooden (Leiden, NL)

9:55 Anti-sense oligonucleotide treatment in HCHWA-D.  
Willeke van Roon (Leiden, NL)

10:25 Hereditary cerebral amyloid angiopathy (HCAA)-type mutations increase β-amyloid’s binding affinity for fibrinogen, delayed fibrinolysis, and fibrin deposit formation in the brains of HCAA patients  
Hyung Jin Ahn (New-York, USA)

10:35 CO2-challenge measured with dual echo arterial spin labeling as a whole brain biomarker of cerebrovascular reactivity in HCHWA-D  
Sophie Schmid (Leiden, NL)

10:45 Coffee Break

11:15 PiB-PET imaging in HCHWA-D in Australia and the Netherlands.  
Jasmeer Chhatwal (Boston, MA, USA)

11:45 Candidate therapy studies for Icelandic-type hereditary CAA  
Hakon Hakonarson (Philadelphia, PA, USA)

12:15 Cerebral amyloid angiopathy influences clinical phenotype in familial Alzheimer’s disease  
Natalie S Ryan (London, UK)

12:25 Imaging characteristics of duplication of the app  
Lou Grangeon (Rouen, France)

12:35 Feasibility of an active immunization clinical trial with a vaccine targeting amyloid-β vaccine in patients with HCHWA-D.  
Kawita Kanhai

Moderators: Hameed Sohradi (Perth, AU) & Marieke Wermer (Leiden, NL)

12:45 Lunch Break
Session 2  2:00- 5:30pm

**Biomarkers of CAA**

Moderators: Fabrizio Piazza (Milan, IT) & Susanna Schraen (Lille, FR)

2:00 MRI Correlates of Autopsy-proven CAA
Konstantinos Arfanakis (Chicago, IL, USA)

2:30 New Insights from PET Molecular Imaging of CAA
Anand Viswanathan (Boston, MA, USA)

3:00 Blood-brain barrier leakage and microvascular lesions in cerebral amyloid angiopathy - A post mortem MRI and histopathology study
Whitney M. Freeze (Boston, USA)

3:10 Evidence for human transmission of amyloid-β cerebral amyloid angiopathy
Zane Jaunmuktane (London, UK)

V. Perosa (Magdeburg, Germany)

3:30 Coffee Break

4:00 Novel body fluid biomarkers for CAA: discovery and clinical implications
Marcel Verbeek (Nijmegen, NL)

4:30 Biomarkers of Cognitive Dysfunction in CAA
Yael Reijmer (Utrecht, NL)

5:00 Blood Metabolomic Profiling in Cerebral Amyloid Angiopathy, Alzheimer’s Disease, and Controls
Shuang Zhao (Alberta, Canada)

5:10 Cerebellar Hemorrhagic Distribution as a New Imaging Marker for Cerebral Amyloid Angiopathy
Hsin-Hsi Tsai (Taipei, Taiwan)

5:20 Blood begets blood”: Cortical superficial siderosis progression in a prospective cohort of cerebral amyloid angiopathy
Thanakit Pongpitakmetha (Boston, USA)

Moderators: Grégoire Boulouis (Paris, FR), & Miyeko Vernooij (NL)

5:30 End of the day

8:30 Gala dinner
Friday, September 7th 2018

Session 3  9:00-12:30

CAA Biology and Physiology
Moderators: Susanne van Veluw (Boston, USA) & Vincent Berezowski (Lille, FR)

9:00 Effect of biological variants of ApoJ and ApoA-I in experimental models of cerebral β-amyloidosis
Mar Hernandez-Guillamon (Barcelona, ES)

9:30 Vasoactive properties of amyloid β isoforms correlate with their specific expression in CAA
Lieke Jäkel (Nijmegen, NL)

10:00 Silent cerebral microbleeds induce long-term cognitive decline in the non-diseased mouse
Maud Pétrault (Lille, France)

10:10 Connexin 43 and Cx43-20kDa isoform lead to vascular injury in cerebral amyloid angiopathy
Svetlana M Stamatovic, (Ann Arbor MI, USA)

10:20 Apolipoprotein D: a potential biomarker for cerebral amyloid angiopathy
H. Bea Kuiperija (Nijmegen, The Netherlands)

10:30 Coffee Break

11:00 Artificial vessels as a model for CAA
Cheryl Wellington (Vancouver, CA)

11:30 Characterization of a novel transgenic rat model for CAA
William van Nostrand, (Kingston, RI, USA)

12:00 Perlecan Domain V as a Novel Treatment for Diabetic Co-morbid Experimental CAA
Amanda Trout, Anika Hartz, Gregory Bix (Lexington, KY)

12:10 Reduced vessel reactivity in mice with vascular Aβ deposition is associated with impaired paravascular clearance
Susanne J. van Veluw (Boston, USA)

12:20 Cerebrovascular smooth muscle cells as the drivers of periarterial lymphatic drainage of the brain
Roxana Aldea, (University of Kentucky, USA)

12:30 Lunch break

Session 4  2:00-3:30pm

Clinical Implications and Therapeutic Dilemmas
Moderator: Karin Klijn (Nijmegen, NL) and Edip Gurol (Boston, USA)

2:00 Can we anticoagulate CAA patients in the context of atrial fibrillation?
Rustam Al-Shahi Salehan (Edinburgh, UK)

2:30 Cognitive impairment in CAA patients: towards a diagnostic and therapeutic approach?
Jérémie Pariente (Toulouse, FR)

3:00 A Cohort Study on the Natural History of Cerebral Amyloid Angiopathy-related inflammation: Evaluation of the Long-Term Outcomes of Immunosuppressive Therapy.
Fabrizio Piazza (Milano, Italy)

3:10 Serum anti-Aβ antibody signatures in cerebral amyloid angiopathy manifestations
Yannick Chantran (Paris, France)
3:20 Cognitive profile of MCI patients with cerebral amyloid angiopathy
An ancillary study of the BALTAZAR cohort
Buard Géraldine (Lille, France)

15:30 Coffee Break

4:00 Transient focal neurological episodes: how to recognize and how to treat?
Speaker: Eric Smith (Calgary, CA)

4:30 The difficult diagnosis of CAA related inflammation

Part 1: Diagnosis
Speaker: Auriel Eytan (Tel Aviv, Israel)

Part 2: Treatment
Speaker: Sonia Alamowitch (Paris, FR)

5:00 Poster walk
Moderators: Grégrory Kuchcinsky (Lille, FR) and Ellis van Etten (Leiden, NL)

5:30 End of the day
Saturday, September 8th 2018

Session 5  9:00-12:30

**Emerging Diagnostic Methods for CAA**

Moderators: Steve Greenberg (Boston, USA) & Stephanie Bombois (Lille, FR)

9:00  CT-based criteria for CAA
Mark Rodrigues (Edinburgh, UK)

9:30  Guidelines for cortical superficial siderosis detection, rating and classification
Frank Wollenweber (Munich, DE)

10:00  Subarachnoid extension of lobar hemorrhage on MRI in the acute and subacute phase is associated with the presence of criteria of probable cerebral amyloid angiopathy
Dimitri Renard (Nimes, France)

10:10  Blood begets blood”: Cortical superficial siderosis progression in a prospective cohort of cerebral amyloid angiopathy
Thanakit Pongpitakmetha (Boston, USA)

10:20  Cerebellar microbleeds distribution and cerebral amyloid angiopathy: an MRI and pathology-based study
Marco Pasi (Boston, USA)

10:30  Coffee Break

11:00  Incidence of cerebral microbleeds and amyloid burden: the Mayo Clinic Study of Aging
Jonathan Graff-Radford (Mayo Clinic, USA)

11:10  Texture-based Individual-level Classification of Normal- Appearing White Matter and White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Healthy Controls
Klourfeld E (Calgary, Canada)

11:20  Pathologic lesions associated with clinical impairment
Julie Schneider (Chicago, IL, USA)

11:50  Boston Criteria version 2.1
Andreas Charidimou (Boston, MA, USA)

Moderators: David Werring (London, UK) and Sarah Shams (Stockholm, SE)

12:30  Conclusion & iCAA 2020

12:45  End of the conference

---

**This conference is supported by**

**ESO**

**EUROPEAN STROKE ORGANISATION**

---

This meeting is endorsed by the European Stroke Organization. It is open to all who are interested in cerebrovascular diseases.

http://www.eso-stroke.org/

Link to the next ESO Conference: http://eso.kenes.com/